Explore
Validate
LearnAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN358271 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (pThr439) antibody
- Antibody type
- Polyclonal
- Description
- Protein A Affinity Chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- pThr439
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at-20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
BRAF kinase gene V599E mutation in growing melanocytic lesions.
BRAF mutations in conjunctival melanoma.
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP
The Journal of biological chemistry 2004 Sep 24;279(39):40419-30
The Journal of biological chemistry 2004 Sep 24;279(39):40419-30
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A
Oncogene 2004 Sep 23;23(44):7436-40
Oncogene 2004 Sep 23;23(44):7436-40
BRAF kinase gene V599E mutation in growing melanocytic lesions.
Loewe R, Kittler H, Fischer G, Faé I, Wolff K, Petzelbauer P
The Journal of investigative dermatology 2004 Oct;123(4):733-6
The Journal of investigative dermatology 2004 Oct;123(4):733-6
BRAF mutations in conjunctival melanoma.
Gear H, Williams H, Kemp EG, Roberts F
Investigative ophthalmology & visual science 2004 Aug;45(8):2484-8
Investigative ophthalmology & visual science 2004 Aug;45(8):2484-8
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL
Cancer research 2004 Aug 15;64(16):5556-9
Cancer research 2004 Aug 15;64(16):5556-9
No comments: Submit comment
No validations: Submit validation data